NCT04093323 2026-02-25
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
Roswell Park Cancer Institute
Phase 2 Terminated
Clinical Trials
6 trialsNCT03734692 2026-02-12
Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer
University of Pittsburgh
Phase 1/2 Active not recruiting
NCT04379518 2026-01-13
Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients
Roswell Park Cancer Institute
Phase 1/2 Terminated
NCT05494697 2025-10-14
Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC
AIM ImmunoTech Inc.
Phase 2 Suspended
NCT03899987 2025-08-27
Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery
Roswell Park Cancer Institute
Phase 2 Active not recruiting
NCT05756166 2025-06-24
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
Roswell Park Cancer Institute
Phase 1/2 Terminated